* Note: Prices are in Million (M) USD.
Description:
Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $270 M
Debt : $4 M
EBITDA : $-522 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Life sciences
Industry: Pharmaceutical preparations
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 11 overlapping fiscal years (max 20).Average Free Cash Flow: $-69 M
Average Revenue: $9 M
Revenue Converted To Free Cash Flow (%): -747.2%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2025-12-31): $19 M
Revenue 5 Years Ago (2020-12-31): $7 M
Total Growth over 5 Years: 174.3%
5-Year Revenue CAGR (Historical): 22.4%
Forward 5-Year CAGR (Tapered): 15.7%
Since historical Revenue CAGR is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2025-12-31): $17 M
Share Count 5 Years Ago (2021-12-31): $41 M
Company is buying back its own shares, 3 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-4.62
Trailing 12-Month Earnings Per Share (EPS): $-4.14
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-4.62
- Latest/TTM EPS: $-4.14
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 6 valid ROE years (max 20).Average ROE: -29.4%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $13.99
52-Week Low: $11.95
Threshold Price (15% Above 52-Week Low): $13.74
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $212 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 0.5% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share, latest positive annual) (2019-12-31): $0.13
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 14 points to above Atrium Therapeutics, Inc. Common Stock (RNA) stock.
Fair Value PE 12, Industry Based PE 14, Growth Based PE 15.65, Risk-Free Anchored PE (25% MoS) 17.65. Based on these 4 values, average assigned is 14.82. The fair value of Atrium Therapeutics, Inc. Common Stock (RNA) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
